Seattle Treatment Education Project

News Flash! The FDA Grants Priority Review to a Co-Formulation of Viread (Tenofovir) and Emtriva (Emtricitabine)

July 27, 2004

Gilead Sciences the maker of Viread and Emtriva announced that the U.S. Food and Drug Administration (FDA) has granted priority review status to a new fixed dose co-formulation of the company's anti-HIV medications Viread and Emtriva.

Under this status, the New Drug Application (NDA) will review the new co-formulation and make a decision by September 12th, 2004. The proposed co-formulation will contain 300 mg of tenofovir (Viread) and 200 mg of emtricitabine (Emtriva). This new medication if it gets approved, will have to be taken in combination with at least one other antiretroviral.

For more information on this news go to: www.Gilead.com.

Back to the STEP Ezine Volume 1, Issue 59 contents page.

This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.

My Health Tracker

Widgets and RSS Feeds

U.S. ASO Finder

The First Man to Be Cured of AIDS: An Update on the Amazing Story -- This Month in HIV

OIs and Co-Infections and STIs -- Oh, My!

HIV Antiretrovirals in Development: An Update From ICAAC 2009

World AIDS Day 2009: Home

Back From the Brink: A Blog Entry by Thomas DeLorenzo

More >>

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.